American CryoStem Announces Patient Treatment Status for its Phase I Clinical Trial for Post-Concussion Syndrome (PCS)

EATONTOWN, NJ / ACCESSWIRE / March 4, 2022 / American CryoStem Corporation (OTC PINK:CRYO) a clinical stage biotechnology company, global licensor, and a pioneer in autologous cellular processing and cellular therapies, announced today that it has …